Related Experiment Video

Updated: May 10, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Tivozanib for the treatment of metastatic renal cancer

Han Hsi Wong1, Tim Eisen

  • 1Cambridge University Health Partners, Addenbrooke's Hospital, Cambridge, UK.

Expert Review of Anticancer Therapy
|June 19, 2013
PubMed

Insights

Tivozanib, a selective VEGF inhibitor, shows improved efficacy and tolerability for metastatic renal cell carcinoma (RCC) compared to sorafenib. Its potential for first-line treatment and combination therapies is promising.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Metastatic renal cell carcinoma (RCC) treatment has been advanced by tyrosine kinase inhibitors (TKIs).
  • Existing TKIs like sorafenib, sunitinib, and pazopanib target the VEGF pathway but cause off-target toxicities.
  • Tivozanib was designed for high potency and selectivity against VEGF receptors 1-3.

Purpose of the Study:

  • To review the laboratory and clinical development of tivozanib.
  • To evaluate tivozanib's efficacy, safety, and pharmacokinetic profile in metastatic RCC.
  • To discuss tivozanib's current and future role in RCC treatment.

Main Methods:

  • Review of preclinical data and clinical trials, including the Phase III TIVO-1 trial.
  • Pharmacokinetic and pharmacodynamic assessments.
  • Comparison of tivozanib with existing therapies like sorafenib.

Main Results:

  • Tivozanib demonstrated superior response rates and progression-free survival compared to sorafenib in the TIVO-1 trial.
  • Tivozanib exhibits a favorable side-effect profile.
  • Early trials suggest good tolerability when combined with mTOR inhibitors like temsirolimus.

Conclusions:

  • Tivozanib is a potent and selective VEGF inhibitor with significant potential in metastatic RCC treatment.
  • It offers an improved efficacy and safety profile over current standard-of-care TKIs.
  • Tivozanib is poised for first-line treatment approval and shows promise in combination therapies.

More Related Videos

Computed Tomography (CT) Guided Implantation of a Totally Implantable Venous Access Port (TIVAP) through Subclavian Vein05:51

Computed Tomography (CT) Guided Implantation of a Totally Implantable Venous Access Port (TIVAP) through Subclavian Vein

Published on: January 13, 2026

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...